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The effect of oxalate, a constituent of renal stone, on
the expression of nuclear pore complex oxalate bind-
ing protein (gp210) in Vero monkey kidney cells was
examined. The expression of this protein was found to
increase more in mitotic phase than in S phase, sug-
gesting cell cycle dependency. Exposure of cells to
oxalate-containing growth medium resulted in a rela-
tive increase in nuclear pore complex oxalate binding
protein in each stage of cell cycle. The concentration
of this protein was found to increase six times in the
telophase stage of the cells exposed to high concentra-
tions of oxalate in the growth medium, though slight
reduction in cell density was observed. Structural an-
alogues of oxalate did not show any stimulatory effect
on expression of this oxalate binding protein. Hence,
the expression of the nuclear pore complex oxalate
binding protein gp210 was specific to oxalate and is
cell cycle dependent. © 1999 Academic Press
Key Words: oxalate binding protein, nuclear pore
complex; gp210; cell cycle.
Urolithiasis is a process of biomineralixation in the
urinary tract. Perturbations in renal oxalate handling
play a major role in renal stone disease (1). Our earlier
studies have shown the presence of about 70% of total
oxalate binding to nuclei while only 30% binding to the
mitochondria (2,3). Our earlier studies have reported the
presence of oxalate binding protein in the nuclear enve-
lope (4). Our preliminary studies have shown that the
nuclear pore complex protein gp210 is an oxalate binding
protein (5). Oxalate has been shown to induce mitosis (6),
DNA synthesis (7), and expression of certain genes (8).
The physiological significance of the presence of oxalate
binding protein in the nuclear pore complex is not well
understood. In order to study its functions, the expression
of this protein during different stages of cell cycle was
studied in the presence of oxalate.
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MATERIALS AND METHODS
Minimum essential medium, penicillin, streptomycin, sodium bi-
carbonate, fetal calfserum, methotrexate, colchicin, Cytochalasin B,
trypsin-EDTA solution, and molecular weight markers were ob-
tained from Sigma Chemical Company, St. Louis, Missouri. Sodium
oxalate, oxamate, malate, citrate. and other chemicals were pur-
chased from Sisco Research Laboratories, Mumbai. Other chemicals
used were of analytical grade and purity.
Human primary biliary cirrhosis (PBC) serum containing autoan-
tibodies against nuclear pore complex protein gp210 was a gift from
Professor Howard J. Worman, Columbia University, New York (9).
Goat anti-human IgG horseradish peroxidase was a gift from NII,
New Delhi.
Cell line and cell culture. Vero monkey kidney cells were serially
passaged in minimal essential medium (MEM) supplemented with
10% fetal calf serum, penicillin (100 U/ml), and streptomycin (100
µg/ml). The cells were maintained in an atmosphere of 5% CO2/95%
air in a humidified 37°C incubator.
Oxalate concentration. Oxalate concentration in the medium was
fixed according to (10) to be 0.1 mM (low), 0.3 mM (medium), and 1
mM (high/toxic) total oxalate (which is equivalent to 30, 100, and 350
µM free oxalate concentrations, respectively). 1 x 105 cells were
incubated with MEM containing specified concentrations of oxalate.
Synchronization at different stages of cell cycle. 1 x 105 cells were
incubated with MEM containing corresponding cell cycle blockers in
25-ml culture flasks. Cells were synchronized at S phase using 10
µg/ml methotrexate, at mitotic phase (metaphase) using 10 µg/ml
colchicin, and at mitotic phase (telophase) using 10 µg/ml Cytocha-
lasin B and the cells were allowed to synchronize for 24 h.
Substrate analogues. 1 x 105 cells were incubated with MEM
containing 0.1 mM oxalate, malate, succinate and citrate and grown
for 24 h.
Trypsinization. Cells were trypsinized by incubating with
trypsin-EDTA solution for 20 minutes, and washed two times by
centrifuging at 2500 rpm/10 minutes with MEM and resuspended
with the same.
Assessment of cell density. From the resuspended pellet, an ali-
quot of the cell was mixed with 0.05% trypan blue. Cells were then
examined immediately under a light microscope and the relative
abundance of the dead (stained) cells was assessed.
Whole cell extract. Whole cell extract was prepared according to
the method of (11). The cells resuspended in MEM was centrifuged at
2500 rpm/5 minutes end resuspended in the lysis buffer (100 mM
Tris-HCl, pH 7.4, containing 1% Triton X-100, 0.4% SDS and 2 mM
EDTA) and incubated for 30 minutes at 4°C. The Triton X-100
extract containing the nuclear pore complex protein was obtained by
centrifuging the whole cell extract at 15,000 rpm/30 minutes. Protein
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TABLE 1
Effect of Oxalate on Cell Density
Particulars % of cell density
0.1 mM Oxalate +25
0.3 mM Oxalate +40
1.0 mM Oxalate -10
Note. +, Increase; -, decrease. Values are means of 3 experiments
with 2 replicates in each experiment. 1 x 105 cells were incubated
with growth medium containing varying concentrations of oxalate.
After 24 h, 10 µl of cells from each category was mixed with 0.05%
trypan blue and the cell density was assessed as described under
Materials and Methods.
concentration was estimated by the method of (12) in the Triton
X-100 extract and in the residual pellet.
ELISA. Enzyme-linked immunosorbent assay was done according
to the method of (13). 30 µg of Triton extract and residual pellet
were coated on 96-well microtitre plates, probed with 1:500 diluted
PBC serum containing autoantibodies against nuclear pore complex
protein gp210, and then incubated with 1:20,000 diluted secondary
antibody (goat anti-human IgG horseradish peroxidase). TMB/H2O2
was added and incubated in dark. The color developed on adding 1 N
H2SO4 was read at 540 nm on a MR600 Dynatech ELISA reader.
The total gp210 concentration (µg/1 x 105) was calculated from a
standard curve obtained by coating varying concentrations of iso-
lated human kidney gp210 (1-10 µg) on 96-well microtitre ELISA
plates and probing with PBC serum (1:500) containing gp210 auto-
antibodies and proceeded as for ELISA.
SDS-PAGE. Triton extracts of unsynchronized and synchronized
cells in the presence of 0.1, 0.3, and 1.0 mM oxalate were electropho-
resed on an 8% mini-gel along with molecular weight markers rang-
ing from 21 to 205 kDa (14) and silver stained by the method of (15).
Statistical analysis. All biochemical values were expressed as
means ± SD of 3 experiments with 2 replicates in each experiment.
The P significance was arrived at using Student’s t test (P < 0.05*;
P < 0.01**; P < 0.001***).
RESULTS
Effect of Oxalate on Cell Density
Exposure of VERO cells to oxalate in the culture
medium produced changes in cell density. 24 h of ex-
posure to varying concentrations (0.1, 0.3, and 1.0 mM
total oxalate) of oxalate produced biphasic effects on
cell numbers. Cells exposed to 0.1 mM total oxalate
showed 25% increase in cell density, cells exposed to
0.3 mM total oxalate showed 40% increase in cell den-
sity, and those exposed to 1.0 mM total oxalate showed
a slight decline of 10% in cell density compared to that
of the control cells unexposed to oxalate (Table 1).
Effect of Oxalate on the Expression of gp210
When the Triton extract of cells grown in 0.1, 0.3,
and 1.0 mM total oxalate were quantitated for gp210
concentration by ELISA, there was a significant in-
crease of 63% (P < 0.01), 155% (P < 0.01), and 450%
FIG. 1. Effect of oxalate on expression of gp210. Values are
means ± SD of 3 experiments with 2 replicates for each experiment.
30 µg of Triton extract was coated onto ELISA plates and probed
with PBC serum containing gp210 autoantibodies (1:500) and the
gp210 concentration was determined as described under Materials
and Methods. Values are statistically significant compared to control
(P < 0.05*; P < 0.01**; P < 0.001***).
(P < 0.001), respectively (Fig. 1). The residual pellet
showed no presence of gp210.
Oxalate Induced and Cell-Cycle-Dependent
Expression of gp210
By ELISA. The concentration of gp210 in synchro-
nized cells grown in the medium containing different
concentrations of oxalate showed an increase compared
to that of the control cells unexposed to oxalate (Fig. 2).
In the S phase, cells exposed to 0.1, 0.3, and 1.0 mM
total oxalate showed a significant increase of 83% (P <
0.05), 152% (P < 0.01), and 213% (P < 0.001) of
gp210 concentration respectively compared to that of
the control S phase cells unexposed to oxalate.
FIG. 2. Oxylate-induced and cell-cycle-dependent expression of
gp210. Values are means ± SD of 3 experiments with 2 replicates for
each experiment. 30 µg of Triton extract was coated onto ELISA
plates and probed with PBC serum containing gp210 autoantibodies
(1:500) and the gp210 concentration was determined as described
under Materials and Methods. Values are statistically significant
compared to control (P < 0.05*; P < 0.01**; P < 0.001***).
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FIG. 3. SDS-PAGE profile of oxalate induced and cell cycle-dependent expression of gp210. Lane 1: S phase cells exposed to 0.1 mM
oxalate. Lane 2: S phase cells exposed to 0.3 mM oxalate. Lane 3: S phase cells exposed to 1.0 mM oxalate. Lane 4: Metaphase cells exposed
to 0.1 mM oxalate. Lane 5: Metaphase cells exposed to 0.3 mM oxalate. Lane 6: Metaphase cells exposed to 1.0 mM oxalate. Lane 7: Telophase
cells exposed to 0.1 mM oxalate. Lane 8: Telophase cells exposed to 0.3 mM oxalate. Lane 9: Telophase cells exposed to 1.0 mM oxalate. Lane
10: Molecular weight markers. 50 µg of Triton extract of cells was electrophoresed on 8% mini-gel along with molecular weight markers and
silver stained as described under Materials and Methods.
In the mitotic phase, cells exposed to 0.1, 0.3, and 1.0 pore complex protein gp210. The physiological impor-
mM total oxalate and synchronized at metaphase tance of this activity with gp210 is not clear. Oxalate
showed a significant increase of 107% (P < 0.01), has been shown to induce mitosis (6) while gp210 is
252% (P < 0.01), and 520% (P < 0.001) of gp210 also reported to be involved in cell cycle (16). In order to
concentration respectively compared to that of the con- understand the role of gp210 during cell cycle, the
trol metaphase cells unexposed to oxalate. The cells expression of this oxalate binding protein during ox-
synchronized at telophase and exposed to 0.1, 0.3, and alate stress condition has been determined.
1.0 mM total oxalate concentration showed a signifi- Lower concentrations of oxalate increase the cell
cant increase of 142% (P < 0.001), 306% (P < 0.001), density while at higher concentration, a slight decline
and 620% (P < 0.001) of gp210 concentration com- in cell density is observed. Available evidence suggests
pared to that of the control telophase cells unexposed to that oxalate levels are about 5-10 µM in the glomeru-
oxalate. Telophase cells exposed to 1.0 mM total ox- lar filtrate (17) and would increase to 50-100 µM in
alate concentration showed the maximum concentra- the proximal tubules. Cortical oxalate levels might
tion of gp210. reach approximately 300 µM free oxalate concentra-
SDS-PAGE. The Triton extracts of synchronized
cells grown in different concentrations of oxalate were
electrophoresed on 8% SDS-PAGE along with molecu-
lar weight markers. Relatively thicker bands were ob-
served in telophase cells with increase in oxalate con-
centration (Fig. 3).
Effect of Substrate Analogues
When cells grown with 0.1 mM oxalate or its
structural analogues—oxamate, malate, succinate, and
citrate-were checked for gp210 concentration, only
cells grown with oxalate showed a significant increase
of 63% (P < 0.01) of gp210 concentration, while others
did not show any significant increase in gp210 concen-
tration (Fig. 4). FIG. 4. Effect of substrate analogues on expression of gp210.
Values are means ± SD of 3 experiments with 2 replicates for each
DISCUSSION experiment. 30 µg of Triton extract was coated onto ELISA platesand probed with PBC serum containing gp210 autoantibodies (1:500)
In our earlier studies, we have shown that nuclear
and the gp210 concentration was determined as described under
oxalate binding activity is associated with the nuclear
Materials and Methods. Values are statistically significant compared
to control (P < 0.01**).
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tion (18). Thus, oxalate might well approach toxic lev-
els in the proximal tubules, particularly in individuals
with hyperoxaluria. High concentrations of oxalate (1.0
mM total oxalate) are toxic to LLC-PKl cells, a line of
renal epithelial cells (10). However, in our study, the
cells exposed to higher concentration of oxalate (1.0
mM total oxalate) have shown an increase in gp210
concentration suggesting an induction of its expression
by oxalate. Further its expression is specific only for
oxalate since its structural analogues show no induc-
tion of gp210 expression.
Though the expression of gp210 is increased at each
stage of the cell cycle on exposure to different concen-
trations of oxalate, the maximal expression of gp210 is
found to be in mitosis (6-fold) rather than in interphase
(2-fold). Gp210 is involved in targeting the pore pro-
teins (19) to facilitate the formation of the pore complex
(20) and also anchors (21) the pore complex during
telophase. Many of the structural modifications of the
cellular architecture that take place in mitosis, includ-
ing nuclear envelope breakdown, occur concurrently
with protein phosphorylation (22, 23). As gp210 is ex-
pressed more in mitosis during oxalate stress condi-
tion, it is suggested that oxalate plays a significant role
in targeting gp210 towards reassembly of nuclear en-
velope for the new daughter cells. As oxalate has been
shown to have mitogenic effect (6), the cell proliferation
may be associated with the induction of gp210. In ad-
dition, oxalate is shown to induce the expression of
c-myc gene (8), and calcium oxalate crystals have been
shown to induce the expression of immediate early
genes c-myc, c-jun, EGR-1 and NVR-77 and genes en-
coding plasminogen activator (PAI-1) (24) and platelet-
derived growth factor (PDGF)-A in BAC-1 kidney epi-
thelial cells in primary cultures of rat proximal tubular
epithelium on exposure to oxidative stress (25).
Under oxalate stress conditions, the intracellular ox-
alate concentration is very high (26) and nuclei contain
2/3 of total oxalate (2). The presence of an oxalate
binding protein in the pore complex may be very sig-
nificant for the accumulation of oxalate in nuclei. Fur-
ther, oxalate is shown to bind histone HlB and has
been suggested to be involved with transcription (27).
Hence, it is concluded that oxalate induces the expres-
sion of the nuclear pore complex oxalate binding pro-
tein gp210 in cell cycle processes.
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